Background: Patients with malignant midgut carcinoids are occasionally diagnosed with limited tumor spread, and surgery with radical intention is performed. Despite curative intent, recurrences occur frequently, motivating long-term biochemical and radiological follow-up. This study aimed to compare the usefulness of various methods in detecting such recurrences. Methods: This retrospective study included 56 patients with radically operated midgut carcinoids referred to our University Hospital for evaluation and follow-up between 1985 and 2004. Patients were monitored 1–3 times per year using plasma-chromogranin A (P-CgA), urinary 5-hydroxyindoleacetic acid (U-5HIAA) concentrations as well as radiological examinations, including ultrasonography, computerized tomography or magnetic resonance investigation. In a subset of cases, somatostatin receptor scintigraphy and/or positron emission tomography with 5-hydroxytryptophan was performed. Time from operation until established recurrence was recorded. Results: Tumor recurrence was established in 33 of 56 patients after a median of 32 months (range 6–217). Elevated P-CgA was the first marker to become pathologically elevated in 28 of these 33 patients (85%). In 3 of these 28 patients, radiology was simultaneously positive for a recurrence. Conclusion: P-CgA was the first marker to indicate tumor recurrence in the majority of radically operated midgut carcinoid patients. To avoid unnecessary and costly examinations in asymptomatic patients, we suggest that follow-up should comprise measurements of P-CgA twice a year and annual ultrasonography until P-CgA is elevated or clinical symptoms occur, at which time all efforts should be made to identify recurrent tumor lesions in order to give the patient the best possible treatment which, if possible, should be surgical removal of the recurrence.

Keywords:
Midgut carcinoid tumor, Chromogranin A, Tumor recurrences
1.
Janson ET, Holmberg L, Stridsberg M, Eriksson B, Theodorsson E, Wilander E, Oberg K: Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol 1997;8:685–690.
2.
Oberg K: The ultimate biochemical diagnosis of gastro-enteropancreatic tumours. Digestion 1996;57(suppl 1):45–47.
3.
Grahame-Smith DG, Peart WS, Ferriman DG: Carcinoid syndrome. Proc R Soc Med 1965;58:701–702.
4.
Akerstrom G, Hellman P, Hessman O, Osmak L: Management of midgut carcinoids. J Surg Oncol 2005;89:161–169.
5.
Moertel CG: Karnofsky Memorial Lecture. An odyssey in the land of small tumors. J Clin Oncol 1987;5:1502–1522.
6.
Wangberg B, Westberg G, Tylen U, Tisell L, Jansson S, Nilsson O, Johansson V, Schersten T, Ahlman H: Survival of patients with disseminated midgut carcinoid tumors after aggressive tumor reduction. World J Surg 1996;20:892–899.
7.
Doherty GM, Olson JA, Frisella MM, Lairmore TC, Wells SA Jr, Norton JA: Lethality of multiple endocrine neoplasia type I. World J Surg 1998;22:581–587.
8.
Norton JA, Fraker DL, Alexander HR, Gibril F, Liewehr DJ, Venzon DJ, Jensen RT: Surgery increases survival in patients with gastrinoma. Ann Surg 2006;244:410–419.
9.
Stridsberg M, Hellman U, Wilander E, Lund- qvist G, Hellsing K, Oberg K: Fragments of chromogranin A are present in the urine of patients with carcinoid tumours: development of a specific radioimmunoassay for chromogranin A and its fragments. J Endocrinol 1993;139:329–337.
10.
Granberg D, Stridsberg M, Seensalu R, Eriksson B, Lundqvist G, Oberg K, Skogseid B: Plasma chromogranin A in patients with multiple endocrine neoplasia type 1. J Clin Endocrinol Metab 1999;84:2712–2717.
11.
Stridsberg M, Eriksson B, Oberg K, Janson ET: A comparison between three commercial kits for chromogranin A measurements. J Endocrinol 2003;177:337–341.
12.
Kolby L, Bernhardt P, Sward C, Johanson V, Ahlman H, Forssell-Aronsson E, Stridsberg M, Wangberg B, Nilsson O: Chromogranin A as a determinant of midgut carcinoid tumour volume. Regul Pept 2004;120:269–273.
13.
Eriksson B, Oberg K: Peptide hormones as tumor markers in neuroendocrine gastrointestinal tumors. Acta Oncol 1991;30:477–483.
14.
Pirker RA, Pont J, Pohnl R, Schutz W, Griesmacher A, Muller MM: Usefulness of chromogranin A as a marker for detection of relapses of carcinoid tumours. Clin Chem Lab Med 1998;36:837–840.
15.
Hsiao RJ, Mezger MS, O’Connor DT: Chromogranin A in uremia: progressive retention of immunoreactive fragments. Kidney Int 1990;37:955–964.
16.
Borch K, Stridsberg M, Burman P, Rehfeld JF: Basal chromogranin A and gastrin concentrations in circulation correlate to endocrine cell proliferation in type-A gastritis. Scand J Gastroenterol 1997;32:198–202.
17.
Sanduleanu S, Stridsberg M, Jonkers D, Hameeteman W, Biemond I, Lundqvist G, Lamers C, Stockbrugger RW: Serum gastrin and chromogranin A during medium- and long-term acid suppressive therapy: a case-control study. Aliment Pharmacol Ther 1999;13:145–153.
18.
Orlefors H, Sundin A, Garske U, Juhlin C, Oberg K, Skogseid B, Langstrom B, Bergstrom M, Eriksson B: Whole-body 11C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography. J Clin Endocrinol Metab 2005;90:3392–3400.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.